An anticoagulant protein was purified from the edible portion of a blood ark shell, *Scapharca broughtonii*, by ammonium sulfate precipitation and column chromatography on DEAE-Sephadex A-50, Sephadex G-75, DEAE-Sephacel, and Biogel P-100. *In vitro* assays with human plasma, the anticoagulant from *S. broughtonii*, prolonged the activated partial thromboplastin time (APTT) and inhibited the factor IX in the intrinsic pathway of the blood coagulation cascade. But, the fibrin plate assay did not show that the anticoagulant is a fibrinolytic protease. The molecular mass of the purified *S. broughtonii* anticoagulant was measured to be about 26.0 kDa by gel filtration on a Sephadex G-75 column and SDSPAGE under denaturing conditions. The optimum activity in the APTT assay was exhibited at pH 7.0-7.5 and 40-45°C in the presence of Ca²⁺.

**Keywords:** Purification, Anticoagulant protein, *Scapharca broughtonii*, Factor IX

**Introduction**

Blood coagulation is processed by coagulation factors in order to stop the flow of blood through the injured vessel wall whenever an abnormal vascular condition and exposure to non-endothelial surfaces at sites of vascular injury occur (Guyton, 1982; Grey and Meyer, 1988). As endogenous or exogenous anticoagulants interfered with the coagulation factors, the blood coagulation can be prolonged or stopped (MacFarlane, 1964; Davey and Ratnoff, 1964; Esmon, 2000). These anticoagulants have been used as convenient tools for the exploration of the complex mechanisms of coagulation cascade. Coincidentally, the importance of research for anticoagulants also arose with therapeutic purposes, for example, a cure for hemophilia. While it was studied for various exogenous anticoagulants (Woo et al., 1996; Waidhet-Kauadio et al., 1998; Kim et al., 1999), anticoagulants from marine organisms have rarely been isolated, except for several anticoagulant proteoglycans and polysaccharides from marine algae (Chargaff et al., 1936 Kindness et al., 1980; Maimone and Tollefsen, 1990; McLellan & Jurd, 1991; Jurd et al., 1995) and ascidian tunic (Lee et al., 1998).

During screening of the anticoagulant activity in marine animals, we recently detected anticoagulant activity from soluble extracts of the blood ark shell, *Scapharca broughtonii*. In the present paper, we report the purification and properties of the first anticoagulant protein from marine bivalves.

**Materials and Methods**

**Materials** Fresh blood ark shells, *Scapharca broughtonii*, were obtained from a blood ark shell aquafarm (Tongyoung, Korea), and kept under −20°C until use. HEMOLAB Thrombomatt, HEMOLAB Silimat, and HEMOLAB Cofac reagent for inhibitory assay were obtained from the BioMerieux Co. (Marcy-l’Etoile, France). BioMerieux Coagulometer Option 8 was a product of Behnk Electronic Co. (Norderstedt, Germany). Fibrinogen (from bovine) and urokinase (from human urine) were purchased from the Sigma Chemical Co. (St. Louis, USA). Molecular weight markers for gel filtration and SDS-polyacryl amide gel electrophoresis were products of the Sigma Chemical Co. (Hercules, USA). DEAE-Sephadex A-50, Sephadex G-75, DEAE-Sephacel, and Biogel P-100 were purchased from the Sigma Chemical Co. (St. Louis, USA). ACE homogenizer AM-6 was a product of Nihonseiki Kaisa Ltd. (Tokyo, Japan). The ultramembrane filter, SM165 (Molecular weight, 10 kDa cut-off), for the concentration of protein solutions was obtained from the Sartorius Co. (Göttingen, Germany). All of the other chemicals that were used in this study were of analytical grade and the highest purity.

**Purification of the anticoagulant from *S. broughtonii*** All of the operations were carried out at 4°C unless stated otherwise. All of the edible parts (100 g) of *S. broughtonii*, except the shell, were minced and homogenized at 10,000 rpm for 10 min in 100 ml of 50 mM Tris-HCl that contained 0.1 mM EDTA, pH 8.0 (Tris-HCl/EDTA) buffer after washing in the same buffer to remove the blood. The insoluble materials were removed by centrifugation at 6,000 × g for 10 min, and the supernatant was treated by 150 ml of 20% CCl₄ (after cooling to −70°C) to remove lipid. Crude extract in
the water layer was dialyzed against 5 mM Tris-HCl buffer (pH 8.0) for 12 h, and tested for their anticoagulant activity using a prothrombin time (PT) and activated partial thromboplastin time (APTT) assay (see below). The extract was desalted out in the range of 20-80% with ammonium sulfate. After centrifugation (8,000 × g, 10 min), the precipitate was collected. The precipitate was dissolved in a Tris-HCl/EDTA buffer; then the dissolved solution was dialyzed against a 5 mM Tris-HCl buffer (pH 8.0) for 12 h. The dialyzed solution was loaded onto a DEAE-Sephadex A-50 column (3 × 40 cm) that was previously equilibrated with a Tris-HCl/EDTA buffer. It was then eluted (0.5 ml/min) with a linear gradient from 0 to 0.5 M NaCl in the same buffer. The eluted fractions at each purification step were tested as to their anticoagulant activity using an APTT assay. The active fraction was pooled, dialyzed against a 5 mM Tris-HCl buffer, and subsequently loaded onto a Sephadex G-75 column (2 × 80 cm, 0.9 ml/min) that was previously equilibrated with a Tris-HCl/EDTA buffer. The elution fraction was pooled, dialyzed, and rechromatographed on a DEAE-Sephadex column (3 × 40 cm) that was previously equilibrated with a Tris-HCl/EDTA buffer. It was then eluted (0.5 ml/min) with a linear gradient from 0 to 0.5 M NaCl in the same buffer. The fraction showing the highest activity was pooled, dialyzed, and rechromatographed on a Biogel P-100 column (2 × 80 cm) that was previously equilibrated with a Tris-HCl/EDTA buffer. It was then eluted (0.9 ml/min) with the same buffer. The major peaks with anticoagulant activity were collected, dialyzed against distilled water, concentrated using the ultramembrane filter (molecular weight, 10 kDa, cut-off membrane), and then lyophilized.

**Measurement of APTT and PT** An in vitro coagulation assay of APTT and PT was performed according to the manufacturers instructions. The citrated normal human plasma (80 μl) and S. broussonetii samples (20 μl) were incubated for 3 min at 37°C. The mixture was activated with 100 μl of HEMOLAB Silimat that contained rabbit brain cephaline or 100 μl of kaolin/saline (5 mg/ml) for 3 min at 37°C. In the PT assay, 200 μl of HEMOLAB Thrombomart contained rabbit brain thromboplastin (thromboplastin c). After 100 μl of 20 mM, CaCl2 was added. The prolonged time (sec) was measured as an inhibitory activity using a Coagulometer Option 8.

**Inhibitory activity for the activated coagulation factors** In the inhibition assay for activated factor IX, 100 μl of the HEMOLAB Cofac IX (containing factor IX-deficient human plasma and 100 μl of HEMOLAB Silimat containing rabbit brain cephaline) were incubated for 3 min at 37°C. Then the mixture of the citrated normal human plasma (80 μl) and S. broussonetii samples (20 μl) (previously incubated for 3 min at 37°C) was added. Subsequently, 100 μl of 20 mM CaCl2 was added and the clotting time was measured. An inhibition activity was calculated as a percent (%) unit by a Coagulometer Option 8. Assays using in vitro diagnostic kits for activated factor XII, XI in the intrinsic pathway and activated factor X in the common pathway, were also performed according to similar methods from the manufacturers instructions. Inhibitory activity against thrombin (factor IIa) was tested with the thrombin assay method of Seegers (1964).

**Fibrinolytic activity** Fibrinolytic activity was assayed using the fibrin plate method (Jespersen and Astrup, 1983). Six milliliters of bovine fibrinogen (3.5 mg/ml in 150 mM barbital buffer, pH 7.75, containing 1 mM CaCl2 and gelatin 0.1%) were placed in a petri dish and clotted by adding 3.6 NIH U of bovine thrombin. After S. broussonetii samples (15 μl, 3-6 replicates/plate) were applied, it was incubated for 18 h at 37°C. Then the lysed areas (mm²) were measured as the product of two perpendicular diameters. Urokinase (15 μl, 25 units/ml) was used as a positive control.

**Measurement of molecular weight** The molecular weight of S. broussonetii anticoagulant was measured by gel filtration on a Sephadex G-75 column (2 × 80 cm) that was previously equilibrated with a Tris-HCl/EDTA buffer. The protein was eluted (0.7 ml/min) with the same buffer. The molecular weight standards were bovine serum albumin (66.0 kDa), carbonic anhydrase (29.0 kDa), cytochrome c (12.4 kDa), and aprotinin (6.5 kDa). A SDS-poly acryl amide gel electrophoresis was performed on 7.5% slab gel by the method of Laemmli (1970). The protein bands were stained with Coomassie Brilliant Blue R-250. The molecular mass standards were fumarase (56.6 kDa), triosephosphate isomerase (32.5 kDa), cytochrome c (12.4 kDa), and aprotinin (6.5 kDa).

**Amino acid composition** The anticoagulant was hydrolyzed with 6 N HCl at 110°C for 24 h in vacuum-sealed ampoules. The amino acids were analyzed with an amino acid analyzer (Biochrom 20, Biochrom Ltd., Cambridge, UK). Cysteine residues were estimated by the method of Spencer and Wold (1969).

**Effects of pH, temperature, and cations on anticoagulant activity** The effects of pH, temperature, and cations of the S. broussonetii extract (20 μl, 25 μg/ml) were measured on the anticoagulant activity.

The pH effect of the anticoagulant protein was measured after the protein was incubated in various buffers for 48 h at 4°C and neutralized. The following buffers were used: 10 mM glycine-HCl, pH 2.5-3.5; 10 mM acetic acid, pH 4.0-5.5; 10 mM phosphate, pH 6.0-7.5; 10 mM Tris-HCl, pH 8.0-9.0; 10 mM glycine-NaOH, pH 9.5-11.0. The residual activity was measured by an APTT assay.

The effect on temperature of the anticoagulant was examined after the protein was incubated in a Tris-HCl/EDTA buffer for 15 min at various temperatures. After cooling to room temperature, the residual anticoagulant activity was examined by an APTT assay.

To test the dependency of the anticoagulant activity on cations, the sample solution was dialyzed against 25 mM EDTA in a Tris-HCl/EDTA buffer at 4°C overnight. Then the solution was dialyzed against deionized water for 24 h in order to remove EDTA. The effect of the cations on APTT was assayed in the presence of various metal cations.

**Other methods** The protein concentration was determined according to the method of Lowry et al. (1951) using bovine serum albumin as a standard. The protein content in all of the fractions that were obtained during the chromatographic process was estimated by the absorbance at 280 nm. The sugar content of the purified anticoagulant was determined by the phenol sulfuric acid method of Dubois et al. (1956) using a
mixture of D-glucosamine and D-galactosamine (1:1) as a standard.

Results and Discussion

Purification of anticoagulant from S. broughtonii As summarized in Table 1, purification of the anticoagulant protein from S. broughtonii was accomplished by the following five steps: desalting out with ammonium sulfate, anion exchange chromatography on a DEAE-Sephadex A-50, gel filtration on a Sephadex G-75, and rechromatography on DEAE-Sephalac and Biogel P-100.

A hundred grams of the samples (all edible parts of S. broughtonii except the shell) were homogenized at 10,000 rpm for 10 min in a 50 mM Tris-HCl buffer that contained 0.1 mM EDTA, pH 8.0 (100 ml, Tris-HCl/EDTA buffer), after washing in the same buffer to remove the blood. Insoluble materials were removed by centrifugation and the supernatants were treated by 150 ml of 20% CCl₄, stored at −70°C to remove lipid in order to prevent deleterious effect, and keep at an optimum anticoagulant activity. The crude extracts, after dialysis, prolonged the clotting time on the activated partial thromboplastin time (APT) assay, but not on the prothrombin time (PT) assay. Thus, the anticoagulant activities at every step were also shown as a prolonged APTT (sec). A 35-s control (100 μl of normal plasma) clotting time was prolonged to 65 s by the addition of 20 μl of the crude extract (15.7 mg/ml). This implies that the soluble extracts from S. broughtonii contain an anticoagulant, which inhibits a specific factor in the intrinsic pathway of the coagulation cascade. The extracts were desalted out in the range of 20-80% saturation with an ammonium sulfate. After dialyzing the precipitate, the sample was applied onto a DEAE-Sephadex A-50 column for the anion exchange chromatography. The results of anion exchange chromatography are shown in Fig. 1a. The anticoagulant activities of the fractions gave several strong peaks. The pooled fraction for gel filtration was eluted from 0.13 to 0.23 M NaCl in a Tris-HCl/EDTA buffer. Although the other fractions showed stronger activities, these activities were deleted in the following process. The gel chromatography, or the quantity, was too small to completely purify to the final process. After dialysis, the active fraction was loaded onto a Sephadex G-75 column and eluted with a Tris-HCl/EDTA buffer. The result of the gel filtration is shown in Fig. 1b. The major anticoagulant active fractions (42-54th) were collected and dialyzed. The dialyzed fraction was rechromatographed on a DEAE-Sephalac, and a major anticoagulant fraction was eluted at 0.1 M NaCl in a Tris-HCl/EDTA buffer (Fig. 1c). Finally, the solution was further fractionated on a Biogel P-100 column after pooling and dialyzing (Fig. 1d). Subsequently, a strong active fraction was eluted with the same buffer and showed a potent anticoagulant activity on an APTT assay.

Properties of anticoagulant protein from S. broughtonii

The result of SDS-PAGE was also shown as a homogeneous protein (Fig. 2, insert). The results of the migration of the incubated anticoagulant protein with 2-mercaptoethanol for 10 min at 95°C revealed only one band with a molecular mass that corresponded to about 26.0 kDa on gel (Lane 1). In addition, the molecular weight of the intact anticoagulant was also estimated to be 26.0 kDa by gel filtration (Fig. 2). The presence of a carbohydrate in the purified anticoagulant was not detected by the phenol-sulfuric acid method. In conclusion, the purified anticoagulant from S. broughtonii is considered to be a pure monomeric protein, while most of natural anticoagulant proteins had a high molecular weight. This is shown as a heterogeneous band pattern in SDS-PAGE, and had been found in most glycoproteins (Garfin, 1990).

Table 1. Purification steps of anticoagulant protein from S. broughtonii

| Step | Total protein (mg) | Total anticoagulation (sec) | Specific anticoagulation Activity (sec/mg) | Purification fold | Yield (%) |
|------|-------------------|----------------------------|------------------------------------------|------------------|-----------|
| Crude extraction | 496.4 | 32414.4 | 653.6 | 1.0 | 100.0 |
| Ammonium persulfate precipitation | 196.2 | 149605.8 | 762.4 | 1.2 | 46.1 |
| Ion exchange chromatography on DEAE-Sephadex A-50 | 21.5 | 28476.8 | 1324.5 | 2.0 | 8.8 |
| Gel chromatography on Sephadex G-75 | 2.2 | 5705.6 | 2641.5 | 4.0 | 1.8 |
| Ion exchange rechromatography on DEAE-Sephalac | 0.3 | 1233.0 | 3977.5 | 6.1 | 0.4 |
| Gel rechromatography on Biogel P-100 | 0.09 | 538.8 | 5986.5 | 9.2 | 0.2 |

*Protein was measured by the method of Lowry et al. (1951).
*The clotting time was measured using the mixture of citrated normal human blood plasma (80 μl) and S. broughtonii anticoagulant (20 μl) by activated partial thromboplastin time assay.
Anticoagulant activities and factor specific inhibitory. As shown in Fig. 3, the purified anticoagulant from S. broughtonii prolonged the activated partial thromboplastin time (APTT), cephaline-induced (or kaolin-induced) clotting times. The addition of 20 μl of the purified anticoagulant (0-100 μg/ml) prolonged a 32 s control-clotting time from 49 s to 325 s (Fig. 3). These results suggest that the soluble extract from S. broughtonii contains an anticoagulant, which inhibits a specific factor in the intrinsic pathway of the coagulation cascade.

As shown in Fig. 4, specific inhibition against factors in the intrinsic pathways' assay showed that the anticoagulant is a potent inhibitor for the activated factor IX. The addition of 20 μl of the purified anticoagulant (0-100 μg/ml) may interfere with the occurrence of coagulation in normal plasma from 20 to 99% in the specific factor IXa inhibition assay. However, the activated factor XI, XII, and others in the intrinsic pathway were not significantly inhibited.

In addition, inhibitory assays against factor Xa and thrombin (factor IIa) in common pathways suggest that the anticoagulant could not suppress the activation of factor X and the ability of thrombin to convert fibrinogen to fibrin in the common pathways. Apitz-Castro et al. (1995) reported that draculin, an anticoagulant glycoprotein of the activated factor IX, was isolated from the saliva of a vampire bat, Desmodus rotundus. The factor IX-binding protein, a potent anticoagulant against factor IX, was also isolated from the venom of Trimeresurus flavoviridis (Atoda & Morita, 1989) and Deinagkistrodon acutus (Atoda et al., 1998). But, the anticoagulant against factor IX from marine organisms has not been reported to our knowledge. The fibrinolytic activity of S. broughtonii extract was undetected in the fibrin plate assay.

Fig. 1. Purification profiles of S. broughtonii anticoagulant. (a) Anion exchange chromatography on a DEAE-Sephadex A-50 column (3 × 40 cm). After being previously equilibrated with 50 mM Tris-HCl that contained 0.1 mM EDTA, pH 8.0 buffer, the fractions were eluted (0.5 ml/min) with a linear gradient from 0 to 0.5 M NaCl in the same buffer. The eluted fractions were collected and tested for their anticoagulant activity using an APTT assay. (b) Gel filtration on a Sephadex G-75 column (2 × 80 cm). The pooled DEAE-Sephadex A-50 fraction was applied to the Sephadex G-75 and eluted with 50 mM Tris-HCl that contained 0.1 mM EDTA, pH 8. buffer at a flow rate of 0.9 ml/min. The active fraction was pooled for next step of purification. (c) Rechromatography on a DEAE-Sephadex column (3 × 40 cm). The sample from the G-75 was loaded onto a DEAE-Sephadex column and eluted (0.5 ml/min) with linear gradient from 0 to 0.5 M NaCl in 50 mM Tris-HCl that contained 0.1 mM EDTA, pH 8.0 buffer. The fraction showing the highest activity was pooled and processed for the next step. (d) Biogel P-100 column chromatography of S. broughtonii anticoagulant. The pooled fraction from the DEAE-Sephadex column was applied to a Biogel P-100 column (2 × 80 cm) and eluted (0.9 ml/min) with 50 mM Tris-HCl that contained 0.1 mM EDTA, pH 8.0 buffer. The active fraction was pooled and contained a homogeneous protein.
An Anticoagulant Protein from *S. broughtonii* 203

Amino acid composition analysis The amino acid composition of the anticoagulant protein is summarized in Table 2. It revealed a high content of Asx, Glx, Leu, and a low content of Cys, His. As reported by Esmen (2000), the hydrophobic interaction, or hydrogen bond between the functional groups (like the carboxyl and hydroxyl groups in the amino acid of the anticoagulant and coagulation factors) might load to inhibit the coagulation pathway in the present of calcium ion, vitamin K, or phospholipid.

Effects on pH, temperature and metal cations The inhibitory activity of the anticoagulant protein from *S. broughtonii* was stable in the range of pH values between 7.0 and 8.0, but the activity at below pH 4.0 and above pH 10.5 was completely destroyed (Fig. 5). The anticoagulant retained its full inhibition activity when maintained at temperatures up to 45°C, but a gradual decrease of activity occurred between 45 and 55°C. The activity was completely inhibited at 55°C (Fig 6). As summarized in Fig 7, the anticoagulant activity was completely deleted, and coagulation did not occur after dialysis with EDTA. Then, the addition of 20 mM of metal divalent cations fairly recovered Cu²⁺ after their removal by...
EDTA. But, the activity in the presence of Ca\(^{2+}\) was more excellent than that of Cu\(^{2+}\). This result suggests that copper could play a role as a substitute of the cofactor, Ca\(^{2+}\), on the blood coagulation system. As reported by Broze et al. (1990) and Davie et al. (1991), the factor IXa activated the factor X in the present of Ca\(^{2+}\) in the intrinsic pathway of the coagulation cascade.

In this study, we discovered that the inhibition mechanism of the anticoagulant from *S. broughtonii* interrupted the factor IXa activity in the intrinsic pathway of the human coagulation cascade in a Ca\(^{2+}\)-dependent manner. Its partial properties were also demonstrated. For a complete structure determination and the molecular mechanisms of the factor IX inhibition, further study will progress in our laboratory.

**Acknowledgments** The Pukyong Research Fund supported this work in 2001.

**Table 2.** Amino acid composition of the anticoagulant protein from *S. broughtonii*

| Amino acids | mol% |
|-------------|------|
| Asx         | 10.379 |
| Thr         | 7.063 |
| Ser         | 6.734 |
| Glx         | 7.136 |
| Pro         | 5.956 |
| Gly         | 9.649 |
| Ala         | 5.556 |
| Cys         | 5.828 |
| Val         | 4.523 |
| Met         | 7.238 |
| Ile         | 4.908 |
| Leu         | 4.090 |
| Phe         | 8.585 |
| His         | 2.150 |
| Lys         | 6.584 |
| Arg         | 3.621 |

**Fig. 5.** Effects of pH on anticoagulant activity. Residual activity on the APTT assay was measured after the anticoagulant (20 µl, 25 µg/ml) was incubated in the various buffers for 48 h at 4 and neutralized. The following buffers were used: 10 mM glycine-HCl, pH 2.5-3.5; 10 mM acetate, pH 4.0-5.5; 10 mM phosphate, pH 6.0-7.5; 10 mM Tris-HCl, pH 8.0-9.0; 10 mM glycine-NaOH, pH 9.5-11.0.

**Fig. 6.** Thermostability of the anticoagulant from *S. broughtonii* was examined after the anticoagulant (20 µl, 25 µg/ml) was incubated in 50 mM Tris-HCl that contained 0.1 mM EDTA, pH 8.0 buffer for 15 min at various temperatures. After cooling at 4°C, the residual anticoagulant activity was examined by APTT assay.

**Fig. 7.** Dependency of anticoagulant activity on cations. The anticoagulant solution (20 µl, 25 µg/ml) was dialyzed against 25 mM EDTA in 50 mM Tris-HCl, pH 8.0 buffer at 4°C overnight. The solution was then dialyzed against deionized water for 24 h in order to remove EDTA. Prolongation of APTT was measured in the presence of each cation.
References

Apitz-Castro, R., Beguin, S., Tablanke, A., Bartoli, F., Holt, J. C. and Hemker, H. C. (1995) Purification and partial characterization of draculin, the anticoagulant factor present in the saliva of vampire bats (Desmodus rotundus). Thromb. Haemost. 73, 94-100.

Atoda, H. and Morita, T. (1989) A novel blood coagulation factor IX/factor X-binding protein with anticoagulant activity from the venom of Trimeresurus flavoviridis (habu snake): Isolation and characterization. J. Biochem. 106, 808-813.

Atoda, H., Ishikawa, M., Mizuno, H. and Morita, T. (1998) Coagulation factor X-binding protein from Deinagkistrodon acutus venom is a gla domain-binging protein. Biochemistry 37, 17361-17370.

Broze, G. J. Jr., Girard, T. J. and Novotny, W. F. (1990) Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry 29, 7539-7546.

Changaff, E., Bancroft F. W. and Stanley-Brown, M. (1936) Studies of chemistry of blood coagulation II. On the inhibition of clotting by substances of high molecular weight. J. Biol. Chem. 115, 155-161.

Davie, E. W. and Ratnoff, O. D. (1964) Waterfall Sequence for Intrinsic Blood Clotting. Science 145, 1310-1312.

Davie, E. W., Fujiwara, K. and Kisiel, W. (1991) The coagulation cascade: Initiation, maintenance, and regulation. Biochemistry 30, 10363-10370.

Dubois, M., Gilles, K. A., Hamilton, J. K., Revers, P. A. and Smith, F. (1956) New colorimetric methods of sugar analysis. The phenol-sulfuric acid reaction for carbohydrates. Anal. Chem. 28, 350-356.

Esmon, C. T. (2000) Regulation of blood coagulation. Biochim. Biophys. Acta 1477, 349-360.

Garfin, D. (1990) One-dimensional gel electrophoresis. Methods Enzymol. 182, 425-441.

Grey, S. V. and Meyer, B. J. (1988) In The Physiological Basis of Medicine, Meyer, B. J. (eds.), pp. 27.1-27.16, HAUM Publishing, Pretoria (in Afrikaans).

Guyton, A. C. (1982) Human Physiology and Mechanisms of Disease, 3rd ed., W. B. Saunders Company, Philadelphia, Pennsylvania.

Jeon, O.-H., Moon, W.-J. and Kim, D.-S. (1995) An anticoagulant/fibrinolytic protease from Lumbricus rubellus. J. Biochem. Mol. Biol. 28, 138-142.

Jespersen, J. and Astrup, T. (1983) A study of the fibrin plate assay of fibrinolytic agents. Optimal conditions, reproducibility and precision. Haemostasis 13, 301-15.

Jurd, K. M., Rogers, K. J., Blunden, G. and McLeUan, D. S. (1995) Anticoagulant properties of sulphated polysaccharides and a proteoglycan from Codium fragile ssp. Atlanticum. J. Appl. Phycol. 7, 339-345.

Kim, G.-M., Yu, K.-H., Woo, J.-I., Bahk, Y.-K., Paik, S.-R., Kim, J.-G. and Chang, C.-S. (1999) A study of the anticoagulatory DNA from the earthworm, Lumbricus rubellus. and its regulatory DNA-binding protein. J. Biochem. Mol. Biol. 32, 567-572.

Kindness, G., Williamson, F. B. and Long, W. F. (1980) Involvement of antithrombin III in anticoagulant effects of sulphated polysaccharides. Biochem. Soc. Trans. 8, 82-83.

Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685.

Lee, K.-H., Choi, B.-D., Hong, B.-I., Jung, B.-C., Ruck, J.-H. and Jung, W.-J. (1998) Functional properties of sulfated polysaccharides in ascidian (Halocynthia roretzi) tunic. J. Korean Fish. Soc. 31, 447-451.

Lowry, O. H., Rosebrough, A. L., Farr, A. L. and Randall, R. J. (1951) Protein measurement with the Folin-phenol reagent. J. Biol. Chem. 193, 265-275.

MacFarlane, R. G. (1964) An Enzyme Cascade in the Blood Clotting Mechanism and its Function as a Biochemical Amplifier. Nature 202, 498-499.

Maimone, M. M. and Tollefsen, D. M. (1990) Structure of a dermatan sulfate hexasaccharide that binds to heparin cofactor II with high affinity. J. Biol. Chem. 265, 18263-18271.

McLeUan, D. S. and Jurd, K. M. (1991) Anticoagulants from marine algae. Blood Coagulation and Fibrinolysis 3, 69-77.

Seegers, W. H. (1964) In Blood coagulation, Hemorrhage and Thrombosis. Tocantins, L. M. and Kazal, L. A. (eds.), pp. 181-187, Grune & Stratton, New York, New York.

Spencer, R. L. and Wold, F. (1969) A new convenient method for estimation of total cystine-cysteine in proteins, Anal. Biochem. 32, 185-190.

Waidhet-Kauadio, P., Yuda, M., Ando, K. and Chize, Y. (1998) Purification and characterization of a thrombin inhibitor from the salivary glands of a malarial vector mosquito, Anopheles stephensi. Biochin. Biophys. Acta 1381, 227-233.

Woo, J.-I., Bahk, Y.-K., Yu, S.-R., Paik, S.-R. and Chang, C.-S. (1996) Evidence for existence of a water-extractable anticoagulant in an earthworm, Lumbricus rubellus. J. Biochem. Mol. Biol. 29, 500-506.
